Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has granted Breakthrough Therapy Designation to daretabart, an anti-GD2 monoclonal antibody, for newly diagnosed high-risk neuroblastoma in pediatric patients. Phase 2 trial data showed a 3-year event-free survival rate of 73.7% when combined with induction chemotherapy — a significant improvement over historical controls. The designation paves the way for accelerated development of this promising treatment.
The FDA has granted Breakthrough Therapy Designation to daretabart (hu14.18K322A), an investigational anti-GD2 humanized monoclonal antibody, for use alongside induction chemotherapy as a first-line treatment for pediatric patients with newly diagnosed high-risk neuroblastoma. The designation was backed by data from the phase 2 NB2012 trial, a single-arm study of 64 children, which demonstrated meaningful improvements over historical chemotherapy-only outcomes.
Daretabart works by targeting GD2, an antigen highly expressed on neuroblastoma cells. It is 98% human, carries a mutation to reduce complement-associated pain, and is engineered to enhance antibody-dependent cell-mediated cytotoxicity — making it a refined successor to dinutuximab. The regimen was generally well tolerated, with grade 3/4 infusion-related adverse effects occurring in a minority of cycles.
By the Numbers:
Why it matters: High-risk neuroblastoma is one of the most challenging pediatric cancers, with historically poor outcomes. This designation accelerates the path toward a potentially more effective and better-tolerated immunotherapy option for children facing this diagnosis.